Spliceosome-regulated RSRP1-dependent NF-κB activation promotes the glioblastoma mesenchymal phenotype.
NF-κB
RSRP1
glioblastoma
mesenchymal phenotype
spliceosome
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
28
5
2021
medline:
6
10
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
The glioblastoma (GBM) mesenchymal (MES) phenotype, induced by NF-κB activation, is characterized by aggressive tumor progression and poor clinical outcomes. Our previous analysis indicated that MES GBM has a unique alternative splicing (AS) pattern; however, the underlying mechanism remains obscure. We aimed to reveal how splicing regulation contributes to MES phenotype promotion in GBM. We screened novel candidate splicing factors that participate in NF-κB activation and MES phenotype promotion in GBM. In vitro and in vivo assays were used to explore the function of RSRP1 in MES GBM. Here, we identified that arginine/serine-rich protein 1 (RSRP1) promotes the MES phenotype by facilitating GBM cell invasion and apoptosis resistance. Proteomic, transcriptomic, and functional analyses confirmed that RSRP1 regulates AS in MES GBM through mediating spliceosome assembly. One RSRP1-regulated AS event resulted in skipping PARP6 exon 18 to form truncated, oncogenic PARP6-s. This isoform was unable to effectively suppress NF-κB. Cotreatment of cultured GBM cells and GBM tumor-bearing mice with spliceosome and NF-κB inhibitors exerted a synergistic effect on MES GBM growth. We identified a novel mechanism through which RSRP1-dependent splicing promotes the GBM MES phenotype. Targeting AS via RSRP1-related spliceosomal factors might constitute a promising treatment for GBM.
Sections du résumé
BACKGROUND
The glioblastoma (GBM) mesenchymal (MES) phenotype, induced by NF-κB activation, is characterized by aggressive tumor progression and poor clinical outcomes. Our previous analysis indicated that MES GBM has a unique alternative splicing (AS) pattern; however, the underlying mechanism remains obscure. We aimed to reveal how splicing regulation contributes to MES phenotype promotion in GBM.
METHODS
We screened novel candidate splicing factors that participate in NF-κB activation and MES phenotype promotion in GBM. In vitro and in vivo assays were used to explore the function of RSRP1 in MES GBM.
RESULTS
Here, we identified that arginine/serine-rich protein 1 (RSRP1) promotes the MES phenotype by facilitating GBM cell invasion and apoptosis resistance. Proteomic, transcriptomic, and functional analyses confirmed that RSRP1 regulates AS in MES GBM through mediating spliceosome assembly. One RSRP1-regulated AS event resulted in skipping PARP6 exon 18 to form truncated, oncogenic PARP6-s. This isoform was unable to effectively suppress NF-κB. Cotreatment of cultured GBM cells and GBM tumor-bearing mice with spliceosome and NF-κB inhibitors exerted a synergistic effect on MES GBM growth.
CONCLUSION
We identified a novel mechanism through which RSRP1-dependent splicing promotes the GBM MES phenotype. Targeting AS via RSRP1-related spliceosomal factors might constitute a promising treatment for GBM.
Identifiants
pubmed: 34042961
pii: 6286882
doi: 10.1093/neuonc/noab126
pmc: PMC8485435
doi:
Substances chimiques
NF-kappa B
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1693-1708Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Nat Immunol. 2013 Jan;14(1):27-33
pubmed: 23179078
Genome Biol. 2009;10(10):242
pubmed: 19857271
J Antibiot (Tokyo). 2004 Mar;57(3):173-9
pubmed: 15152802
Brain. 2019 Aug 1;142(8):2352-2366
pubmed: 31347685
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
J Clin Invest. 2014 Dec;124(12):5411-23
pubmed: 25365225
Int J Oncol. 2012 Dec;41(6):2079-86
pubmed: 23042038
Blood. 2016 Jul 7;128(1):82-92
pubmed: 27127301
Nat Commun. 2014 Jul 21;5:4426
pubmed: 25043379
Nat Rev Drug Discov. 2012 Nov;11(11):847-59
pubmed: 23123942
Genome Biol. 2016 Jun 10;17(1):125
pubmed: 27287018
Brain. 2018 Apr 1;141(4):961-970
pubmed: 29522154
Cancer Cell. 2018 Jul 9;34(1):85-102.e9
pubmed: 29990503
Cancer Discov. 2019 Nov;9(11):1556-1573
pubmed: 31455674
Biochem Pharmacol. 2011 Feb 1;81(3):412-24
pubmed: 21040711
Cancer Cell. 2016 Feb 8;29(2):201-13
pubmed: 26859459
Nat Commun. 2013;4:1683
pubmed: 23575687
Oncotarget. 2016 Apr 5;7(14):18812-24
pubmed: 26934315
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Lancet. 2018 Aug 4;392(10145):432-446
pubmed: 30060998
J Biol Chem. 2004 Jun 4;279(23):24246-54
pubmed: 15010457
BMC Cancer. 2009 Oct 19;9:372
pubmed: 19840379
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Neuro Oncol. 2016 Mar;18(3):329-39
pubmed: 26534766
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Nature. 2015 Sep 17;525(7569):384-8
pubmed: 26331541
Cancer Discov. 2019 Sep;9(9):1248-1267
pubmed: 31201181
Sci Adv. 2016 Jan 08;2(1):e1501292
pubmed: 26824076
Mol Cell. 2017 May 18;66(4):503-516.e5
pubmed: 28525742
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
J Neurooncol. 2018 Jul;138(3):499-508
pubmed: 29876787
Genome Med. 2018 Jul 24;10(1):57
pubmed: 30041684
Nat Commun. 2012;3:1061
pubmed: 22990857
Genes Dev. 1998 Apr 1;12(7):996-1009
pubmed: 9531537
Cancer Sci. 2014 Jan;105(1):110-6
pubmed: 24635824
Adv Exp Med Biol. 2007;623:107-22
pubmed: 18380343
BMC Med Genomics. 2019 Nov 15;12(1):165
pubmed: 31729991
Circ Res. 2016 Aug 19;119(5):652-65
pubmed: 27418629